Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Pubmed

Protein-protein interactions between large proteins: two-hybrid screening using a functionally classified library composed of long cDNAs.

CEP152 FBXO21 FOXJ3

2.82e-061308312421765
Pubmed

Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.

CEP152 FBXO21

2.27e-041008210048485
ToppCellCerebellum-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_1-Endothelial_Tip.Dcn.Nnat_(Nnat)|Cerebellum / BrainAtlas - Mouse McCarroll V32

ZKSCAN7 SFRP4

2.15e-04126826d5075d659dac7b96e6857f8485a7d2c4105d685
ToppCellCerebellum-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_1-Endothelial_Tip.Dcn.Nnat_(Nnat)-|Cerebellum / BrainAtlas - Mouse McCarroll V32

ZKSCAN7 SFRP4

2.15e-0412682fd0001a0f3a0a4421f96fd21813c21cf6f01d40e
ToppCellCerebellum-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_1|Cerebellum / BrainAtlas - Mouse McCarroll V32

ZKSCAN7 SFRP4

2.15e-0412682f20424f9baf3c4059cd6b701761e7595400fc47c
ToppCellCerebellum-Endothelial-ENDOTHELIAL_TIP-Dcn_2|Cerebellum / BrainAtlas - Mouse McCarroll V32

ZKSCAN7 SFRP4

2.15e-041268283f3540683b3b175b10af059ab8898c46eaccc13
ToppCellE16.5-samps-Mesenchymal-Myofibroblast-Proliferative_Immature_MyoFibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass

ZKSCAN7 CEP152

2.47e-0413582ed0f94d3839eea3b60217c4352159ed481361f13
ToppCelldroplet-Liver-HEPATOCYTES-1m-Epithelial-Hepatocyte_(Pericentral)|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FBXO21 PTPRD

3.47e-0416082c42bcc6c7d113f0db43febb088b75ca4ac7cb7a3
ToppCellBasal_cells-Donor_03|World / lung cells shred on cell class, cell subclass, sample id

ZKSCAN7 PAEP

3.64e-0416482b15a26130a1ea1b370b6e3be21f02a0d6aaf6b3c
ToppCell356C-Fibroblasts-Fibroblast-D-|356C / Donor, Lineage, Cell class and subclass (all cells)

ZKSCAN7 SFRP4

3.73e-04166827c2eee0a4f45795a956acf936b85bdb35f1b1624
ToppCell356C-Fibroblasts-Fibroblast-D|356C / Donor, Lineage, Cell class and subclass (all cells)

ZKSCAN7 SFRP4

3.73e-04166827286a37b2827f3747469ffd0d76cbe81116db7ee
ToppCellPND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC-ILC_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ZKSCAN7 CEP152

3.82e-0416882a7eb28e15b591997f1aee09501cb20ae18beca08
ToppCell10x_5'_v1-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia/MHC|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SFRP4 PTPRD

3.92e-0417082fb6098137d010175978596bc382e9ecba9c3891e
ToppCell10x_5'_v1-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia/MHC-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SFRP4 PTPRD

3.92e-0417082dfef8f79960979335b86b4730f224239b40735d5
ToppCell343B-Fibroblasts-Fibroblast-B_(Myofibroblast)-|343B / Donor, Lineage, Cell class and subclass (all cells)

SFRP4 PTPRD

4.24e-041778243ba6f12c2fb32698a420bf799d46ac1b558f146
ToppCell343B-Fibroblasts-Fibroblast-B_(Myofibroblast)|343B / Donor, Lineage, Cell class and subclass (all cells)

SFRP4 PTPRD

4.24e-0417782e55d21d4d61a069b9bbe0e7595fbfb7cfbacfd87
ToppCell3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

SFRP4 PTPRD

4.24e-04177827af1a19692f7fe8f691178a4e57d62bc379e3d56
ToppCellCOVID-19_Convalescent-PLT_1|World / Disease Group and Platelet Clusters

FBXO21 YLPM1

4.34e-0417982d0f2764c6fc5d61fd69e9231b3603a80ac373f65
ToppCellprimary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

CEP152 PTPRD

4.39e-04180825391d23817f5cc88a0871ddb98968897c839f464
ToppCellMesenchymal_cells-Adipo-CAR|Mesenchymal_cells / Lineage and Cell class

SFRP4 PTPRD

4.44e-04181821cfb03eb03a37b036b4eeacec69c9b8163af1ee4
ToppCellChildren_(3_yrs)-Epithelial-club_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

PAEP PTPRD

4.48e-0418282215c303df42f13597b2c7a95cb157c6bc7aca9a1
ToppCellSomatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

CEP152 PTPRD

4.58e-04184826475a43201b136dcc9b113d2ca4cfa154ed9d65d
ToppCelldroplet-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l1|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

SFRP4 PTPRD

4.68e-04186824e983de6d2515082f9e555f4f949cec84281c140
ToppCell343B-Fibroblasts-Fibroblast-E|343B / Donor, Lineage, Cell class and subclass (all cells)

SFRP4 PTPRD

4.68e-041868259db239f1864a5d4f1570c93219dbd7ac5b6db35
ToppCell343B-Fibroblasts-Fibroblast-E-|343B / Donor, Lineage, Cell class and subclass (all cells)

SFRP4 PTPRD

4.68e-04186821bac7825c2fe3e6cdff65026b09b9ccaa40fa27f
ToppCell(0)_MSCs-(00)_Lepr-MSC|World / Cell class and subclass of bone marrow stroma cells in homeostatis

SFRP4 PTPRD

4.68e-0418682f0d156167d7cc2cd8a76e5a364233e9f2170bc01
ToppCell(0)_MSCs|World / Cell class and subclass of bone marrow stroma cells in homeostatis

SFRP4 PTPRD

4.68e-0418682a832c1e0035bcd559722eccf262c145deb3494c7
ToppCellMesenchymal_cells-Adipo-CAR|World / Lineage and Cell class

SFRP4 PTPRD

4.68e-04186826ca8ce7ced91d6308b7c056032ffec1b37c974bf
ToppCellAdult-Epithelial-club_cell-D231|Adult / Lineage, Cell type, age group and donor

PAEP PTPRD

4.73e-0418782ee59d7d3de5879738ff0b9c3ea5e4847fb48cb86
ToppCell5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

SFRP4 PTPRD

4.94e-04191820fae1c2ef9f83ac7721d0a9d69455bf97eed9257
ToppCellASK440-Mesenchymal|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq

SFRP4 PTPRD

4.94e-0419182f12959eebb4167e1aa03de05d7711a702c58b3c9
ToppCellASK440-Mesenchymal-Fibroblast|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq

SFRP4 PTPRD

4.94e-0419182387296b5377ef6839f0812e5b3529a10b5f7d530
ToppCell5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

SFRP4 PTPRD

4.99e-0419282b9e4585bea280ca0ae159f0c6a2bf7b88a15a6e6
ToppCellnucseq-Epithelial-Epithelial_Alveolar-Secretory/RAS|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

PAEP PTPRD

5.09e-04194820cd4363627acd419e00d6d32f6dce10430aa6487
ToppCellnucseq-Epithelial-Epithelial_Alveolar-Secretory/RAS-RAS|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

PAEP PTPRD

5.09e-0419482a58841b34efe673671a9a059238e044a7254b279
ToppCellFibroblasts-DKK3+_Fibroblasts|Fibroblasts / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues

SFRP4 PTPRD

5.20e-041968224d64b67aa9b0e8215ad06f9101c1314b3483620
ToppCellCOPD-Epithelial-Club|Epithelial / Disease state, Lineage and Cell class

PAEP PTPRD

5.20e-0419682af96fb94886e9395f3e2cd0a293af29229d017fe
ToppCell3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

SFRP4 PTPRD

5.25e-04197826b6440f1baad5680cf9e13ca3ab72a2c65523d59
ToppCell10x3'2.3-week_14-16-Mesenchymal_osteo-stroma-early_osteoblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

SFRP4 PTPRD

5.30e-04198826a539d3b47bd2d4a7ad5c67cad23facffc0ac45f
ToppCellFibroblasts-DKK3+_Fibroblasts|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues

SFRP4 PTPRD

5.30e-04198824f4632f26a2043c5e4ab89031b4229b5dca1bd48
ToppCell10x3'2.3-week_14-16-Mesenchymal_osteo-stroma|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

SFRP4 PTPRD

5.36e-04199827b1b3b108d817fb3b50a710c3146b30bcf9c2f6b
ToppCell10x3'2.3-week_14-16-Mesenchymal_osteo|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

SFRP4 PTPRD

5.36e-0419982f2ad641f36c577ff7019e88ad6b73ed7e46d8c74
ToppCellBiopsy_Other_PF-Mesenchymal-Myofibroblasts|Biopsy_Other_PF / Sample group, Lineage and Cell type

SFRP4 PTPRD

5.41e-0420082e504570fd7eec1524c401b1cfa9d10822d80d994
ToppCell10x5'v1-week_17-19-Mesenchymal_osteo-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SFRP4 PTPRD

5.41e-04200823c898e81444b001835c3f1bbc68183078701b135
ToppCellBiopsy_IPF-Mesenchymal-Myofibroblasts|Biopsy_IPF / Sample group, Lineage and Cell type

SFRP4 PTPRD

5.41e-0420082c2c6f687c49ba790174b27c7b8b084af30b34c86
ToppCellBiopsy_IPF-Mesenchymal-Fibroblasts|Biopsy_IPF / Sample group, Lineage and Cell type

SFRP4 PTPRD

5.41e-0420082d8637f1e62d3fb9476dc51e1b1dc2f4b14b5fcd8
ToppCell10x5'v1-week_17-19-Mesenchymal_osteo|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SFRP4 PTPRD

5.41e-04200823eca8ffeb41b664fbdbbd70b375c5d953503ab29
DrugAC1NP8CI

ZKSCAN7 PAEP

1.47e-051782CID005153863
DrugMetanephrine hydrochloride DL [881-95-8]; Up 200; 17.2uM; MCF7; HT_HG-U133A

CEP152 SFRP4 PTPRD

3.41e-05196831515_UP
Drug0225151-0000 [351320-15-5]; Up 200; 10uM; PC3; HT_HG-U133A

FBXO21 FOXJ3 SFRP4

3.46e-05197836389_UP
DrugSulfamethoxypyridazine [80-35-3]; Up 200; 14.2uM; PC3; HT_HG-U133A

CEP152 FBXO21 SFRP4

3.51e-05198833711_UP
DrugChloramphenicol [56-75-7]; Up 200; 12.4uM; PC3; HT_HG-U133A

CEP152 FBXO21 FOXJ3

3.51e-05198835047_UP
DrugApramycin [37321-09-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A

CEP152 FOXJ3 YLPM1

3.62e-05200834959_DN
Drugfelodipine; Up 200; 10uM; MCF7; HT_HG-U133A_EA

FOXJ3 YLPM1

1.51e-0317082965_UP
Drugprochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HT_HG-U133A_EA

CEP152 FOXJ3

1.56e-0317382995_UP
DrugPyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; MCF7; HT_HG-U133A

CEP152 YLPM1

1.78e-03185825439_DN
DrugMethyl benzethonium chloride [25155-18-4]; Up 200; 8.6uM; PC3; HT_HG-U133A

PAEP SFRP4

1.80e-03186823768_UP
DrugClioquinol [130-26-7]; Up 200; 13uM; MCF7; HT_HG-U133A

SFRP4 PTPRD

1.82e-03187825258_UP
DrugTriamcinolone [124-94-7]; Up 200; 10.2uM; HL60; HG-U133A

FBXO21 YLPM1

1.84e-03188821395_UP
DrugScoulerine [6451-73-6]; Up 200; 12.2uM; HL60; HG-U133A

CEP152 YLPM1

1.86e-03189821742_UP
Drughaloperidol; Up 200; 10uM; MCF7; HT_HG-U133A

FOXJ3 YLPM1

1.86e-03189826960_UP
DrugLY 294002; Up 200; 10uM; PC3; HT_HG-U133A

CEP152 FOXJ3

1.90e-03191821227_UP
Drug17-AAG; Up 200; 1uM; PC3; HT_HG-U133A

CEP152 YLPM1

1.90e-03191824442_UP
DrugHarpagoside [19210-12-9]; Down 200; 8uM; MCF7; HT_HG-U133A

CEP152 YLPM1

1.90e-03191824981_DN
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

CEP152 YLPM1

1.90e-03191821080_UP
Drug17-DMAG; Up 200; 0.1uM; MCF7; HT_HG-U133A

FOXJ3 YLPM1

1.90e-03191826933_UP
DrugPF-00562151-00 [351320-12-2]; Up 200; 10uM; MCF7; HT_HG-U133A

FBXO21 SFRP4

1.90e-03191825917_UP
DrugHaloperidol [52-86-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A

SFRP4 PTPRD

1.94e-03193825273_UP
DrugMinocycline hydrochloride [13614-98-7]; Up 200; 8uM; PC3; HT_HG-U133A

FBXO21 SFRP4

1.96e-03194825077_UP
DrugThioguanosine [85-31-4]; Up 200; 12.6uM; HL60; HT_HG-U133A

FOXJ3 YLPM1

1.96e-03194821264_UP
DrugCarbetapentane citrate [23142-01-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A

FBXO21 PTPRD

1.96e-03194825610_UP
DrugClobetasol propionate [25122-46-7]; Up 200; 8.6uM; MCF7; HT_HG-U133A

FBXO21 SFRP4

1.96e-03194826835_UP
DrugFenspiride hydrochloride [5053-08-7]; Up 200; 13.4uM; HL60; HG-U133A

YLPM1 PTPRD

1.96e-03194821422_UP
DrugGSK-3 Inhibitor IX; Up 200; 0.5uM; MCF7; HT_HG-U133A

FOXJ3 SFRP4

1.96e-03194826589_UP
Drugprazosin hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA

CEP152 YLPM1

1.96e-0319482942_UP
DrugThalidomide [50-35-1]; Up 200; 15.4uM; MCF7; HT_HG-U133A

FBXO21 SFRP4

1.96e-03194822258_UP
DrugPrednicarbate [73771-04-7]; Down 200; 8.2uM; MCF7; HT_HG-U133A

CEP152 YLPM1

1.96e-03194825544_DN
DrugThioguanosine [85-31-4]; Down 200; 12.6uM; HL60; HT_HG-U133A

CEP152 YLPM1

1.96e-03194821264_DN
Drugsemustine; Up 200; 100uM; PC3; HT_HG-U133A

YLPM1 PTPRD

1.96e-03194827492_UP
DrugGraveoline [485-61-0]; Up 200; 14.4uM; PC3; HT_HG-U133A

CEP152 FBXO21

1.96e-03194823716_UP
DrugResveratrol [501-36-0]; Up 200; 17.6uM; MCF7; HT_HG-U133A

ZKSCAN7 SFRP4

1.98e-03195822865_UP
DrugClenbuterol hydrochloride [21898-19-1]; Down 200; 12.8uM; MCF7; HT_HG-U133A

CEP152 YLPM1

1.98e-03195825631_DN
DrugHesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A

SFRP4 YLPM1

1.98e-03195825313_UP
DrugProbucol [23288-49-5]; Up 200; 7.8uM; MCF7; HT_HG-U133A

ZKSCAN7 SFRP4

1.98e-03195825261_UP
DrugSulfacetamide sodic hydrate [6209-17-2]; Down 200; 15.8uM; HL60; HT_HG-U133A

CEP152 FBXO21

1.98e-03195821859_DN
DrugTomatidine [77-59-8]; Down 200; 9.6uM; HL60; HG-U133A

CEP152 FBXO21

1.98e-03195821754_DN
Drugalpha-estradiol; Up 200; 0.01uM; PC3; HT_HG-U133A

ZKSCAN7 SFRP4

1.98e-03195824434_UP
DrugSparteine (-) [90-39-1]; Up 200; 17uM; MCF7; HT_HG-U133A

FBXO21 SFRP4

1.98e-03195822790_UP
DrugHydralazine hydrochloride [304-20-1]; Up 200; 20.4uM; MCF7; HT_HG-U133A

PAEP SFRP4

1.98e-03195824746_UP
DrugCiprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A

SFRP4 YLPM1

1.98e-03195825299_UP
Drugvalinomycin; Down 200; 0.1uM; PC3; HT_HG-U133A

FBXO21 YLPM1

1.98e-03195825911_DN
DrugPentetic acid [67-43-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A

FBXO21 SFRP4

2.00e-03196825629_UP
DrugKawain [500-64-1]; Up 200; 17.4uM; PC3; HT_HG-U133A

FBXO21 FOXJ3

2.00e-03196827369_UP
DrugBeclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A

FBXO21 SFRP4

2.00e-03196824580_DN
DrugCoralyne chloride hydrate [38989-38-7]; Down 200; 9.6uM; MCF7; HT_HG-U133A

CEP152 SFRP4

2.00e-03196825418_DN
DrugScopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; PC3; HT_HG-U133A

CEP152 YLPM1

2.00e-03196826335_DN
DrugTubocurarine chloride pentahydrate (+) [6989-98-6]; Up 200; 5.2uM; HL60; HG-U133A

CEP152 YLPM1

2.00e-03196821738_UP
DrugPhthalylsulfathiazole [85-73-4]; Up 200; 10uM; MCF7; HT_HG-U133A

CEP152 FBXO21

2.00e-03196823371_UP
Drug0393-0188; Down 200; 10uM; MCF7; HT_HG-U133A

FOXJ3 SFRP4

2.00e-03196827531_DN
DrugHippeastrine hydrobromide [22352-41-6]; Up 200; 10uM; MCF7; HT_HG-U133A

ZKSCAN7 FBXO21

2.00e-03196826042_UP
DrugDosulepin hydrochloride [897-15-4]; Up 200; 12uM; HL60; HG-U133A

CEP152 YLPM1

2.00e-03196821713_UP
Drugclozapine; Up 200; 10uM; MCF7; HT_HG-U133A

FOXJ3 SFRP4

2.00e-03196825226_UP
DrugMetanephrine hydrochloride DL [881-95-8]; Up 200; 17.2uM; HL60; HG-U133A

FBXO21 YLPM1

2.00e-03196822015_UP
Drug(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Up 200; 12.2uM; MCF7; HT_HG-U133A

YLPM1 PTPRD

2.00e-03196825533_UP
DrugDyclonine hydrochloride [536-43-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A

CEP152 YLPM1

2.00e-03196827022_DN
Drug(1)-Nipecotic acid [498-95-3]; Up 200; 31uM; MCF7; HT_HG-U133A

FBXO21 SFRP4

2.00e-03196825999_UP
DrugIproniazide phosphate [305-33-9]; Down 200; 14.4uM; PC3; HT_HG-U133A

FBXO21 YLPM1

2.02e-03197826359_DN
DrugPropranolol hydrochloride [318-98-9]; Up 200; 13.6uM; PC3; HT_HG-U133A

FBXO21 SFRP4

2.02e-03197826759_UP
DrugAzathioprine [446-86-6]; Up 200; 14.4uM; MCF7; HT_HG-U133A

CEP152 PTPRD

2.02e-03197821528_UP
DrugN6,2-O-dibutyryladenosine 3,5-cyclic monophosphate sodium salt; Up 200; 2uM; MCF7; HT_HG-U133A_EA

CEP152 YLPM1

2.02e-0319782959_UP
DrugGleevec; Down 200; 10uM; PC3; HG-U133A

SFRP4 PTPRD

2.02e-0319782483_DN
DrugEvoxine [522-11-2]; Up 200; 11.6uM; PC3; HT_HG-U133A

CEP152 PTPRD

2.02e-03197823681_UP
DrugTriflusal [322-79-2]; Up 200; 16.2uM; HL60; HG-U133A

CEP152 YLPM1

2.02e-03197821717_UP
DrugPramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A

FBXO21 PAEP

2.02e-03197826054_UP
DrugTriflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; HL60; HT_HG-U133A

FBXO21 YLPM1

2.02e-03197821855_DN
DrugCefadroxil [50370-12-2]; Up 200; 11uM; MCF7; HT_HG-U133A

FBXO21 PTPRD

2.02e-03197824161_UP
DrugMetolazone [17560-51-9]; Up 200; 11uM; MCF7; HT_HG-U133A

CEP152 SFRP4

2.02e-03197821514_UP
DrugRibostamycin sulfate salt [53797-35-6]; Down 200; 7.2uM; MCF7; HT_HG-U133A

CEP152 FOXJ3

2.02e-03197823444_DN
DrugFluorocurarine chloride [22273-09-2]; Up 200; 11.6uM; PC3; HT_HG-U133A

FBXO21 SFRP4

2.02e-03197825741_UP
DrugPirenzepine dihydrochloride [29868-97-1]; Up 200; 9.4uM; HL60; HG-U133A

FBXO21 YLPM1

2.02e-03197821388_UP
DrugImidurea [39236-46-9]; Down 200; 10.4uM; MCF7; HT_HG-U133A

FOXJ3 YLPM1

2.02e-03197825481_DN
DrugAmpicillin trihydrate [7177-48-2]; Up 200; 10uM; MCF7; HT_HG-U133A

CEP152 SFRP4

2.02e-03197821530_UP
DrugDehydrocholic acid [81-23-2]; Up 200; 9.6uM; MCF7; HT_HG-U133A

SFRP4 PTPRD

2.02e-03197825681_UP
Diseasepathological myopia

SFRP4 PTPRD

3.87e-0411182EFO_0004207
DiseaseColorectal Neoplasms

SFRP4 PTPRD

2.37e-0327782C0009404
Diseasehippocampal volume

SFRP4 PTPRD

2.72e-0329782EFO_0005035
Diseaseparental longevity

YLPM1 PTPRD

7.33e-0349482EFO_0007796
DiseaseMammary Neoplasms, Human

PAEP PTPRD

8.24e-0352582C1257931
DiseaseMammary Carcinoma, Human

PAEP PTPRD

8.24e-0352582C4704874
DiseaseMammary Neoplasms

PAEP PTPRD

8.30e-0352782C1458155
DiseaseBreast Carcinoma

PAEP PTPRD

8.64e-0353882C0678222
Diseaseage at menarche

FOXJ3 PTPRD

1.05e-0259482EFO_0004703
Diseasewellbeing measurement

YLPM1 PTPRD

1.40e-0269282EFO_0007869
DiseaseColorectal Carcinoma

SFRP4 PTPRD

1.44e-0270282C0009402

Protein segments in the cluster

PeptideGeneStartEntry
HHPEQLEMSWNEQML

CEP152

66

O94986
TCMMGHEWIRNMNVH

FBXO21

526

O94952
TWHSMAMATNNISLM

PAEP

36

P09466
HHRAMNQQHMMPSQA

FOXJ3

586

Q9UPW0
TMDPTQHVNNWMKHN

PTPRD

456

P23468
MCRHMPWNITRMPNH

SFRP4

31

Q6FHJ7
NKMADHWETAPRHMM

YLPM1

1981

P49750
QWNMMPENHHSMASL

ZKSCAN7

256

Q9P0L1